What is the survival rate of Kymriah?
Kymriah (tisagenlecleucel) is a CAR T-cell therapy used to treat certain types of relapsed or refractory (r/r) blood cancers. Ongoing clinical studies continue to assess its long-term survival rates.
Currently, the available data shows the survival rate is 87.7% for patients with relapsed or refractory follicular lymphoma at 24 months after the Kymriah infusion, and 43.6% for patients with aggressive B-cell non-Hodgkin’s lymphoma. The 5-year survival rate for patients with advanced B-cell acute lymphoblastic leukemia is 55%.
Survival Rates by Cancer Type
Children and young adults with advanced B-cell acute lymphoblastic leukemia (ALL)
The five-year overall survival rate in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) is 55%. This means that 55% of patients treated with Kymriah were still alive after 5 years. This data is from the ELIANA clinical trial that included 79 patients.
Adults with relapsed or refractory diffuse large B-cell lymphoma
According to the Center for International Blood and Marrow Transplant Research CIBMTR, the 24-month overall survival rate was 43.6% out of 1159 patients receiving Kymriah for aggressive B-cell non-Hodgkin’s lymphoma. Another study reported a 12-month survival rate of 59%.
Adults with relapsed or refractory follicular lymphoma
In the ELARA study, the estimated 24-month progression-free survival was 57.4%. The overall survival was 87.7%. The ELARA study included 97 patients.
These findings highlight Kymriah’s potential benefits in various blood cancers, though research is ongoing to confirm long-term efficacy.
References
Awasthi, R., et. al. 2023. Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy. In: Human Vaccines and Immunotherapeutics. DOI: https://doi.org/10.1080/21645515.2023.2210046
Dreyling, M., et. al. 2022. Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial. In: Blood. DOI: https://doi.org/10.1182/blood-2022-158024
Kymriah [package insert]. Updated June 2024. Novartis Pharmaceuticals Corporation. Accessed August 2, 2024 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
Novartis. June 12, 2022. Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL. Accessed August 2, 2024 at https://www.novartis.com/news/media-releases/novartis-five-year-kymriah-data-show-durable-remission-and-long-term-survival-maintained-children-and-young-adults-advanced-b-cell-all
Read next
What is CAR T-cell therapy and how does it work?
CAR T-cell therapy is a personalized treatment that uses a patient's own immune cells to fight certain cancers and autoimmune diseases. By harnessing and reprogramming a patient’s own immune cells, this therapy offers a new option for those who have not responded to conventional treatments.
Continue reading
What is the cost of Kymriah?
Kymriah (tisagenlecleucel) is an expensive CAR-T cell cancer therapy costs over $633,000 for one treatment, but most people do not pay this amount. In addition, the Centers for Medicare & Medicaid Services (CMS) states that CAR-T cell therapy would be covered for eligible people with Medicare.
Continue reading
What's the difference between Kymriah and Yescarta?
Kymriah and Yescarta are two cell-based gene therapies. A few differences between the two medications include who and what they are FDA approved for, their dosage, and which companies make them.
Continue readingSee also:
Related medical questions
- How is Kymriah administered?
- What type of drug is Kymriah (tisagenlecleucel)?
- How does Besponsa work to treat Acute Lymphoblastic Leukemia (ALL)?
- What is the lifetime or cumulative dose for Adriamycin?
- What to avoid when taking Gleevec?
- How much does Blincyto (blinatumomab) cost?
- Is there a generic for Gleevec?
- Gleevec vs Sprycel vs Tasigna - how do they compare?
- How long does it take Sprycel (dasatinib) to start working?
- How much does Tecartus cost?
- How does Gleevec (imatinib) work?
- Is Sprycel a chemotherapy drug?
- Is Tasigna a form of chemotherapy?
- Is Tecartus a one-time treatment?
- Is Blincyto (blinatumomab) chemotherapy?
- How does Asparlas (calaspargase pegol-mknl) compare to Oncaspar (pegaspargase)?
- How is Blincyto administered?
- Can I take Gleevec while pregnant?
- What is the difference between Truxima and Rituxan?
- What is the success rate of Rituxan (rituximab) in patients with blood cancers?
- Does Truxima make you gain weight?
- What are the names of the BTK inhibitors?
- What is the cost of Yescarta?
- How does Monjuvi work?
- What is Zydelig used for and how does it work?
- What is the difference between Rituxan and Rituxan Hycela?
- How is Monjuvi given / administered?
- What is the success rate of Epkinly?
- How is Rituxan Hycela administered?
- What is the success rate of Breyanzi?
Drug information
- Kymriah Information for Consumers
- Kymriah prescribing info & package insert (for Health Professionals)
- Side Effects of Kymriah (detailed)
Related support groups
- Kymriah (6 questions, 3 members)
- Acute Lymphoblastic Leukemia (23 questions, 15 members)
- Follicular Lymphoma (21 questions, 15 members)
- Diffuse Large B-Cell Lymphoma (19 questions, 3 members)
- B Cell Lymphoma (10 questions, 3 members)